“Some of the things that they can do is [implementing] innovative technology, whether that’s a way to deliver the product to their client, whether that’s automating applications, or figuring out a way to [improve] the ease of doing…
Source: www.insurancebusinessmag.com – Read more
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
